Curanex Pharmaceuticals Inc. (CURX) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Curanex Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing botanical drugs for inflammatory diseases. The Company completed its Initial Public Offering (IPO) in August 2025 and trades on the Nasdaq Capital Market. Its lead candidate, Phyto-N, is in preclinical development for indications including ulcerative colitis and cancer cachexia.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,441,198) | $(197,929) |
| Net Loss Per Share (Basic & Diluted) | $(0.23) | $(0.01) |
| Operating Expenses | $6,508,919 | $195,110 |
| Cash Used in Operating Activities | $(2,034,671) | $(440,029) |
| Cash and Cash Equivalents (End of Period) | $2,938,463 | $108,862 |
| Total Assets | $5,073,932 | $11,580,124 (Dec 31, 2025) |
| Total Liabilities | $286,254 | $361,040 (Dec 31, 2025) |
Material Changes vs. Prior Period
- Expense Surge: Operating expenses increased significantly from $195,110 in the prior year period to $6.51 million. This was driven by a $4.85 million increase in Research & Development (R&D) and a $1.46 million increase in General & Administrative (G&A) expenses.
- R&D Activity: The increase in R&D reflects post-IPO investments in IND-enabling studies (toxicology, pharmacokinetics) and CMC activities for Phyto-N. A significant portion of current expenses is funded by the drawdown of prepaid R&D balances, which decreased by approximately $4.35 million.
- G&A Drivers: Higher G&A costs are attributed to increased payroll for senior management (who began receiving cash compensation post-IPO) and costs associated with public company compliance.
- Liquidity: While cash balances decreased by approximately $2.03 million during the quarter, the Company maintains a positive cash position of $2.94 million, a substantial increase from the $108,862 held at the end of the prior year period following the IPO.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern. Current cash reserves are not expected to fund operations for at least twelve months from the filing date. The Company plans to raise additional capital through equity or debt offerings, but there is no assurance of success.
- Nasdaq Compliance: The Company received a second 180-day compliance period from Nasdaq to meet the $1.00 minimum bid price requirement. To address this, the Board approved a 1-for-20 reverse stock split, expected to become effective in August 2026.
- Development Milestones: The Company targets an Investigational New Drug (IND) application submission for ulcerative colitis in the fourth quarter of 2026. A Phase I trial is planned to commence 30 days post-submission if approved.
- Equity Plan: The 2026 Equity Incentive Plan was adopted, reserving 5.7 million shares. While no awards were granted as of June 30, 2026, the Company issued 3 million shares under this plan in July/August 2026.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" regarding going concern status and the consumption of prepaid R&D balances.
- Reverse Stock Split: Confirm the effectiveness date of the 1-for-20 reverse stock split and its impact on the minimum bid price compliance.
- Prepaid R&D Utilization: Monitor the rate at which prepaid R&D balances are consumed; cash burn is expected to accelerate as these prepayments are exhausted.
- IND Submission: Track progress toward the Q4 2026 IND submission target for ulcerative colitis.
- Internal Controls: Review subsequent filings for remediation plans regarding the ineffective disclosure controls and procedures.